Modified-release dosage

Controlled & Modified Drug Release Summit 2023: The Next Generation of Drug and Therapeutic Delivery is Here (Princeton, NJ, United States - May 16-17, 2023) - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 13, 2022
Health, Pharmaceutical, Therapy, Modified-release dosage, Next Generation, MRNA, Generic drug

The "2023 Controlled & Modified Drug Release Summit" conference has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "2023 Controlled & Modified Drug Release Summit" conference has been added to ResearchAndMarkets.com's offering.
  • The next generation of drug and therapeutic delivery is here.
  • Attend and connect with 160+ senior drug development innovators this May and uncover the industry's latest formulation and delivery technologies for improving drug product performance and developing next-gen products.
  • Uncover a multitude of new product development strategies, formulation approaches, and delivery technologies in just 2 days.

NATROLⓇ INTRODUCES SLEEP+ CAPSULES TO ENHANCE YOUR SLEEP WITH ESSENTIAL WELLNESS BENEFITS

Retrieved on: 
Tuesday, June 7, 2022
Exercise, Science, Life, Vitamin, Adult, Rest, LLC, Food, Supplement, News, Food and Drug Administration, Disease, Solution, Multimedia, Walgreens, Sleep, Mineral, Modified-release dosage, Health, New Mountain Capital, Target Corporation, Twitter, The Non-GMO Project, Instagram, Capsule, Pharmaceutical industry, Dietary supplement, Beauty, Facebook, Melatonin, Immunity, Green tea

CHATSWORTH, Calif., June 7, 2022 /PRNewswire/ -- Natrol, the #1 drug-free sleep aid brand in America,^ announced the launch of Natrol Sleep+ Capsules - a new line of melatonin supplements, uniquely formulated with clean ingredients to support your sleep and provide added muscle recovery, immune health, and calming benefits. The innovative new line is an expansion of Natrol's award-winning Sleep+ suite of products which bring together the benefits of melatonin with secondary ingredients to plus up your sleep.†

Key Points: 
  • Natrol crafted the new Sleep+ Capsules line with whole-body wellness in mind to support both a person's sleep and other wellness needs while they rest.
  • Natrol will debut a new wellness benefit to the brand's Sleep+ portfolio with the launch of Sleep+ Recovery within the line.
  • Natrol Sleep+ Calm Capsules: Designed to help relax the mind and reduce occasional stress, this tranquil blend helps ease you to sleep.
  • To learn more about Natrol Sleep+ Capsules and Natrol's other superior melatonin forms, including Natrol Sleep+ Gummies, Fast Dissolve, Time Release and Liquid, visit www.Natrol.com .

Pharvaris Presents Clinical Data on Oral PHA121 Supporting the Prophylactic Treatment of Hereditary Angioedema at the EAACI Annual Congress 2021

Retrieved on: 
Friday, July 9, 2021
Health sciences, Pharmacology, Dosage forms, Pharmaceutical sciences, Tablet, Capsule, Formulation, Modified-release dosage, Softgel

The data also show that PHA121 was well absorbed with median times to reach peak plasma levels within 1.00 to 1.75 hours after dosing with standard meals.

Key Points: 
  • The data also show that PHA121 was well absorbed with median times to reach peak plasma levels within 1.00 to 1.75 hours after dosing with standard meals.
  • Pharvaris remains committed to providing patients with oral alternatives both for on-demand and prophylactic treatment in HAE via our softgel capsule formulation, PHVS416, and extended-release tablet formulation, PHVS719.
  • Pharvaris is developing this formulation to provide rapid exposure of attack-mitigating medicine in a convenient, small oral dosage form.
  • Pharvaris is developing this novel small molecule for on-demand and prophylactic treatment of HAE and other bradykinin-mediated diseases through formulations optimized for each setting.

PLx Pharma Inc. to Present at Upcoming Healthcare Industry Conferences

Retrieved on: 
Wednesday, June 9, 2021
Health sciences, Pharmacology, Drugs, Hepatotoxins, Dosage forms, Aspirin, Commercialization of traditional medicines, Pharma, Modified-release dosage

It also reduces the risk of stomach erosions and ulcers, as compared to immediate-release aspirin, common in an acute setting.

Key Points: 
  • It also reduces the risk of stomach erosions and ulcers, as compared to immediate-release aspirin, common in an acute setting.
  • PLx Pharma Inc. is a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard drug delivery platform to provide more effective and safer products.
  • The PLxGuard drug delivery platform works by targeting the release of active pharmaceutical ingredients to various portions of the gastrointestinal (GI) tract.
  • To learn more aboutPLx Pharma Inc. and its pipeline, pleasevisit www.plxpharma.com .

UroGen Pharma Announces June 2021 Conference Schedule

Retrieved on: 
Tuesday, May 25, 2021
Biotechnology, Pharmaceutical, Health, Oncology, Health sciences, Life sciences, Pharmacology, Biotechnology, Pharmaceutical industry, Colloidal chemistry, Gels, Hydrogel, Water chemistry, Modified-release dosage, Urology, Biopharmaceutical

A replay of each webcast will be available on the website for approximately 30 days.

Key Points: 
  • A replay of each webcast will be available on the website for approximately 30 days.
  • UroGen is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options.
  • UroGen has developed RTGel reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs.
  • UroGen is headquartered in Princeton, NJ with operations in Israel.

UroGen Pharma Reports First Quarter 2021 Financial Results and Recent Corporate Developments

Retrieved on: 
Thursday, May 13, 2021
Oncology, Health, Hospitals, Other Health, Pharmaceutical, Biotechnology, Health sciences, Pharmacology, Health, Breakthrough therapy, Orphan drugs, Antineoplastic drugs, Aziridines, Enones, Mitomycin C, Hydrogel, Fast track, Modified-release dosage, Jelmyto®, Upper Tract Urothelial Cancer (UTUC), UGN-102, the Phase 3 ATLAS Trial, UroGen Pharma Ltd., JELMYTO®, UPPER TRACT UROTHELIAL CANCER (UTUC), UGN-102, THE PHASE 3 ATLAS TRIAL, UROGEN PHARMA LTD.

The U.S. FDA previously granted Orphan Drug, Fast Track, and Breakthrough Therapy Designations to Jelmyto for the treatment of LG-UTUC.

Key Points: 
  • The U.S. FDA previously granted Orphan Drug, Fast Track, and Breakthrough Therapy Designations to Jelmyto for the treatment of LG-UTUC.
  • It is important that you receive all 6 doses of JELMYTO according to your healthcare provider\xe2\x80\x99s instructions.
  • If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment.
  • UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs.

How to Select the Right Polymers for your Modified Release Tablet or Capsule, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Friday, March 12, 2021
Health sciences, Pharmacology, Pharmaceutical sciences, Dosage forms, Pharmaceutical industry, Pharmacokinetics, Pharmacy, Routes of administration, Modified-release dosage, Tablet, Capsule, Excipient

Often, modified release (MR) formulations offer patient compliance, marketing and exclusivity/patent benefits over immediate-release versions.

Key Points: 
  • Often, modified release (MR) formulations offer patient compliance, marketing and exclusivity/patent benefits over immediate-release versions.
  • What isn't as obvious is that MR dosage forms present their own unique set of complications around excipient selection.
  • In this webinar, panelists will discuss the most common polymers used in modified release oral solid dosage form development.
  • For more information, or to register for this event, visit How to Select the Right Polymers for your Modified Release Tablet or Capsule.

PLx Pharma Inc. to Present at the Oppenheimer 31st Annual Healthcare Conference

Retrieved on: 
Thursday, March 11, 2021
Pharmacology, Health sciences, Drugs, Hepatotoxins, Dosage forms, Aspirin, Commercialization of traditional medicines, Pharma, Drug delivery, Modified-release dosage

It also reduces the risk of stomach erosions and ulcers, as compared to immediate-release aspirin, common in an acute setting.

Key Points: 
  • It also reduces the risk of stomach erosions and ulcers, as compared to immediate-release aspirin, common in an acute setting.
  • PLx Pharma Inc. is a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard drug delivery platform to provide more effective and safer products.
  • The PLxGuard drug delivery platform works by targeting the release of active pharmaceutical ingredients to various portions of the gastrointestinal (GI) tract.
  • To learn more aboutPLx Pharma Inc. and its pipeline, pleasevisit www.plxpharma.com .

PLx Pharma Inc. to Discuss 2020 Fourth Quarter Financial Results on March 12, 2021 Conference Call and Provide Business Update

Retrieved on: 
Thursday, March 4, 2021
Pharmacology, Health sciences, Drugs, Hepatotoxins, Routes of administration, Dosage forms, Pharmacokinetics, Aspirin, Pharma, Drug delivery, Modified-release dosage

A replay of the conference call will be available for two weeks after the call's completion by dialing (855) 859-2056 (U.S.) or (404) 537-3406 (International).

Key Points: 
  • A replay of the conference call will be available for two weeks after the call's completion by dialing (855) 859-2056 (U.S.) or (404) 537-3406 (International).
  • It also reduces the risk of stomach erosions and ulcers, as compared to immediate-release aspirin, common in an acute setting.
  • PLx Pharma Inc. is a late-stage specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard drug delivery platform to provide more effective and safer products.
  • The PLxGuard drug delivery platform works by targeting the release of active pharmaceutical ingredients to various portions of the gastrointestinal (GI) tract.

UroGen Pharma Announces March 2021 Conference Schedule

Retrieved on: 
Tuesday, February 23, 2021
Biotechnology, Pharmaceutical, Health, Oncology, Health sciences, Life sciences, Pharmacology, Biotechnology, Pharmaceutical industry, Colloidal chemistry, Gels, Hydrogel, Water chemistry, Urology, Modified-release dosage, Biopharmaceutical

A replay of each webcast will be available on the Companys website for approximately 30 days.

Key Points: 
  • A replay of each webcast will be available on the Companys website for approximately 30 days.
  • UroGen is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options.
  • UroGen has developed RTGel reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs.
  • UroGen is headquartered in Princeton, NJ with operations in Israel.